TB Drug Accelerator (TBDA) Program
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2012
- Initiating Organization: BGMF
- Initiator Type: Nonprofit foundation
- Rare disease
- Disease focus:
Tuberculosis - Location: International
Abstract
The TB Drug Accelerator (TBDA) Program targets the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA Program is to create a tuberculosis (TB) drug regimen that cures patients in only one month, rather than the six months now needed for treatment.
Mission
The TBDA Program aims to develop five new preclinical drug candidates with treatment-shortening potential within five years and proof of concept for a one-month, three-drug regimen within 10 years.
Consortium History
April 2012: TBDA Program launched
Financing
The program is supported by $20 million from the Bill & Melinda Gates Foundation.
Links/Social Media Feed
Homepage |
http://partnerships.ifpma.org/partnership/tb-drug-accelerator-program |
Sponsors & Partners
AbbVie |
AstraZeneca |
Bayer HealthCare |
Bill & Melinda Gates Foundation |
Eisai |
Eli Lilly and Company |
GlaxoSmithKline |
MSD |
Sanofi |
Global Alliance for TB Drug Development (TB Alliance) |
Infectious Disease Research Institute |
Texas A&M University |
US National Institutes of Health |
Weill Medical College |
Cornell University |